An unexpected diagnostic course of systemic lupus erythematosus

Aysel Taktak¹, Adem Köksoy¹, Özge Başaran¹, Saba Kiremitçi², Banu Acar¹ Nermin Uncu¹, Nilgün Çakar¹

¹Department of Pediatric Nephrology and Rheumatology, Ankara Child Health, Hematology, Oncology Training and Research Hospital, ²Department of Pathology, Ankara University Faculty of Medicine.

E-mail: aysel.taktak@gmail.com

Received: 3 June 2015, Revised: 16 September 2015, Accepted: 14 October 2015


Thrombotic microangiopathy (TM), especially thrombotic thrombocytopenic purpura (TTP) is described in systemic lupus erythematosus (SLE) as a severe hematological involvement. However hemolytic uremic syndrome (HUS) is seen less frequently in SLE, particularly as an initial presentation. Here we present a 15-year old boy presenting with gross hematuria, decreased urinary output and petechial lesions. He was diagnosed as atypical HUS according to the classical triad of TM, along with observation of hypocomplementemia and negative stool cultures. In addition, his symptoms fulfilled the 2012 revised criteria for the classification of SLE. He was treated with plasma infusions and methylprednisolone/prednisone. At follow up his laboratory findings and general condition improved and no relapse was seen.

Key words: systemic lupus erythematosus, thrombotic microangiopathy, child.

Hemolytic uremic syndrome (HUS) is characterized by the triad of microangiopathic anemia, thrombocytopenia and kidney injury¹. HUS is classified into three categories: 1) Typical disease which occurs sporadically or epidemically due to Shiga toxin producing E. coli, 2) Familial atypical cases due to genetic abnormalities of complement regulatory proteins and 3) Sporadic atypical cases which are secondary to infections, medications, malignancy or systemic diseases such as systemic lupus erythematosus (SLE)². Thrombotic microangiopathy (TM) is common during the course of SLE especially in antiphospholipid antibody syndrome³. In SLE patients, TM is seen as a result of direct antiglobulins, antiplatelet antibodies and anti-endothelial antibodies⁴. However atypical HUS is a rare clinical presentation of SLE⁵.

Here we present a 15-year old adolescent whose initial presentation was atypical HUS as a rare manifestation of SLE.

Case Report

A 15-year-old boy was admitted with anorexia, vomiting, gross hematuria and decreased urine output for two days. There was no history of fever, dysuria, upper respiratory tract infection or diarrhea. He was taking levothyroxine 300 mcg/day for 3 years with the history of total thyroidectomy due to multinodular dysmorphgenetic goiter.

On physical examination, pallor petechial lesions on the cheeks, chest and lower extremities and pretibial edema were observed. His blood pressure was 130/85 mm Hg. The rest of the physical examination was unremarkable.

The initial laboratory analysis revealed: hemoglobin, 7 g/dl (12.8-16 g/dl), platelet count, 5000/mm³ (150.000-450.000/mm³), reticulocyte count 9.3%, lactate dehydrogenase (LDH) level 2255 U/l (0-248 U/l), serum urea 69 mg/dl (11-39 mg/dl), creatinine 1.22 mg/dl (0.5-1.2 mg/dl), serum proteins and electrolytes were in normal range. Peripheral blood smear showed macrocytic hypochromic anemia, anisopoikilocytosis composed of schistocytes. His direct antiglobulin (Coombs’) test was 3 (+). Erythrocyte sedimentation rate was 46 mm/h, C-reactive protein was 7.6 mg/dl (0-8 mg/dl).
The urine was dark brown macroscopically. Urinalysis revealed 3 (+) proteinuria and 3 (+) hematuria with 76 dysmorphic erythrocytes per high power field. Spot urine protein/creatinine ratio was 3.8. 24-hour urine collection revealed nephrotic range proteinuria (56 mg/m²/h). The urine and blood cultures showed no growth.

Renal ultrasound revealed kidneys with normal shape and size but renal cortical echogenicity was markedly increased.

The patient had hemolytic anemia, thrombocytopenia and renal impairment, with no history of fever, dysuria, upper respiratory tract infection or diarrhea. Therefore the most likely diagnosis was atypical HUS or less likely thrombotic thrombocytopenic purpura (TTP).

For differential diagnosis serum complement level 3 (C3), ADAMTS13 activities, and anti-ADAMTS13 antibody was performed. His C3 level was 54 mg/dl (83-177 mg/dl). ADAMTS13 activity was 98 % and anti-ADAMTS13 antibody was 6.4 U/mL (normal < 15 U/ml). However HUS could not explain the positive direct Coombs’ test result, therefore auto antibodies such as antinuclear antibody (ANA), anti-double stranded (ds) DNA antibodies, anti-cardiolipin and anti-phospholipid antibodies were tested. ANA was 3 (+), anti-ds DNA antibody was 666.5 IU/ml (0-200 IU/ml), anti-cardiolipin and anti-phospholipid antibodies were negative. Echocardiography revealed minimal pericardial effusion. These symptoms and findings met the Systemic Lupus International Collaborating Clinics criteria, 2012 (SLICC)⁵, he was also diagnosed as SLE.

The cause of proteinuria may both be due to lupus nephritis and hemolytic uremic syndrome. Percutaneous renal biopsy was performed with the thrombocyte count of 147,000/mm³. Light microscopic examination of the renal biopsy revealed diffuse moderate glomerular mesangial hypercellularity with mesangial widening and glomerular capillary thrombosis in one glomeruli (Fig. 1). The immunofluorescence study showed “full house” immunoglobulin deposition (IgG, IgA, IgM) together with diffuse C3 and C1q deposition in glomerular mesangial areas (Fig. 2). Histopathologic examination was consistent with lupus nephritis (Class II of the International Society of Nephrology/Renal Pathology Society 2003) and HUS.

Fresh frozen plasma was initiated at 10 ml/kg twice a day. Methylprednisolone pulses (30 mg/kg/dose, maximum 1 g) were initiated on the second day given for five days consecutively, followed by oral prednisone (2 mg/kg/day), hydroxychloroquine (5 mg/kg/day) and enalapril (0.1 mg/kg/day). After the first month of treatment, oral steroid was tapered gradually. At the end of six months, the prednisone dose was 20 mg/day. His laboratory examination was as follows: 24-hour urine protein excretion 7.6 mg/m²/h, urea 30 mg/dl, creatinine 0.65 mg/dl, hemoglobin 13 g/dl, platelet count 258000/mm³, C3 level was 94 mg/dl. He had no relapse during follow up.
Discussion

Systemic lupus erythematosus is an autoimmune disease characterized by the production of wide spread autoantibodies which leads to immune complex deposition, inflammation or organ damage. It may affect many organs and may cause various clinical features such as skin rash, arthritis, serositis and involvement of the kidney, lung, central nervous system and hematologic system.

Thrombotic microangiopathy in SLE may result from TTP and less frequently from HUS or rarely from a direct endothelial injury triggered by anti-endothelial antibodies, malignant hypertension or calcineurin inhibitor-associated. In TM, cytopenias are mediated by mechanical hemolysis revealed by schistocytes, whereas in SLE, an autoimmune process is involved, revealed by positive tests for direct antiglobulin and anti-platelet antibodies.

A major feature of SLE is the formation of immune complexes. These immune complexes trigger the complement system and lead to activation of the classical pathway with C4b and C3b deposition which can covalently bind to glomerular endothelial surfaces and basement membranes through the thiol ester site, mounting of the membrane attack complex (C5b–9), release of C3a and C5a anaphylatoxins and commonly causing cellular injury and tissue inflammation. Complement is consumed in active SLE, resulting in hypocomplementemia (typically low C4 and C3).

Atypical HUS is one of the diseases causing TM. Atypical HUS manifests as a microangiopathic disease with mechanical anemia, thrombocytopenia and acute renal failure. The clear link between aHUS and the complement pathway is well recognized. Mutations have been identified in factor H, MCP, factor I and thrombomodulin (THBD). These proteins act as regulating factors of the C3 convertase. The rate of activation of the alternative pathway outstrips the rate of downstream regulatory processes on endothelial cells leading to their injury. Low C3 is seen in/or less than 50% of the patients. Therefore C3 antigen measurement is not an adequate screening test for aHUS because a normal result does not rule out a function altering mutation and the same conclusion can be applied to factors H, I, and B.

Complement consumption is seen during SLE flares, which could lead to endothelial activation, as observed in congenital HUS. This phenomenon might explain one of the links between lupus nephritis and HUS. Furthermore, it has been shown that some non-shiga toxin-associated HUS are not caused by mutations of regulatory proteins of the complement alternative pathway like FH and cofactor protein (CD46), but occur in the context of an autoimmune disease with the development of anti-factor H antibodies leading to an acquired factor H deficiency.

Although no significant difference in the presence of fever, neurological disorder, anemia and negative Coombs’ test was noticed between lupus patients with and without TM, the clinical evidence of microangiopathic hemolytic anemia (MAHA) such as elevated LDH and the presence of increased peripheral schistocytes may be helpful in identifying TTP–HUS clinically in patients with lupus nephritis. Renal histopathology could provide solid evidence of TM.

In our case, there was no history of bloody diarrhea, stool culture was negative, LDH was increased, C3 level was decreased, peripheral schistocytes was increased, ADAMTS 13 and anti-ADAMTS13 antibody levels were in normal range, and therefore aHUS was primarily thought. Factor H antibody could not be measured. As direct Coombs’ test was positive, viral serologic tests and auto antibodies were performed. According to ANA and anti-ds DNA positivity, serositis and renal histopathologic and immunofluoresan findings, he has been diagnosed as SLE based on the SLICC criteria. Although there is a high prevalence of thyroid nodules in SLE patients, our case had histopathologically proven multinodular dysmorphgenetic goiter and his autoimmune thyroid markers were negative (anti thyroid peroxidase antibody was 7.2 IU/ml (0-9) and anti-thyroglobulin was 0.1 IU/ml (0-4)), which is not relevant to SLE.

Treatment options include plasma infusion or plasma exchange within 24 hours of diagnosis and immunosuppressive medications; although there is no well established guideline for treatment of HUS in patients with lupus nephritis. Our patient achieved clinical remission of both lupus nephritis and
thrombotic microangiopathy after plasma therapy and immunosuppressive treatment.

In conclusion, in a patient presenting with hemolytic anemia, examination of the peripheral blood smear is very important for early diagnosis of TM. SLE should be suspected in all TM patients because of overlapping clinical and biological manifestations, such as hemolytic anemia, thrombocytopenia and renal impairment.

REFERENCES


